sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_6 ;
    pav:version "1.4" .
  sub:_5 prov:value "Surprisingly, CSC (1, 2.5, and 5%) treatments did not cause any appreciable increase in NF-kB transactivation at 24 h in A549 cells. In preliminary studies, treatment of rat type II epithelial (L2) cells with CSC (1, 5, and 10%) for 4 h did not increase NF-kB DNA binding as assessed by electrophoretic mobility gel shift assay (data not shown) suggesting that CSC has no effect on NF-kB activation or transactivation in epithelial cells as revealed by various techniques. We also assessed the translocation of the p65 subunit of NF-?B from the cytoplasm to nucleus using the Cellomics Arrayscan technology. Using this technique, we showed increased nuclear p65 in response to IL-1b treatment (Fig. 7B), whereas CSC did not result in translocation of p65 from the cytoplasm to nucleus (data not shown)." ;
    prov:wasQuotedFrom pubmed:15456740 .
  sub:_6 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:15456740 ;
    prov:wasDerivedFrom beldoc: , sub:_5 .
}